dx 8951 has been researched along with Benign Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Agama, KK; Arakawa, Y; Bindra, RS; Choi, WS; Gayle, S; Jo, U; Jones, K; Murai, Y; Paralkar, V; Pommier, Y; Saha, LK; Sun, Y; Sundaram, RK; Van Doorn, J; Vasquez, JC; Yang, X | 1 |
| Gayle, S; Jones, K; Paradis, T; Paralkar, VM; Vasquez, J | 1 |
| Ashley, GW; Carreras, CW; Fontaine, SD; Reid, RR; Santi, DV | 1 |
| Abe, M; Abe, Y; Agatsuma, T; Hashimoto, Y; Hayakawa, I; Hirotani, K; Iguchi, T; Ishizaka, T; Kagari, T; Kamai, Y; Kaneda, Y; Karibe, T; Koyama, K; Maeda, N; Morita, K; Murakami, M; Nakada, T; Nomura, T; Ogitani, Y; Shiose, Y; Ueno, S; Wakita, K; Zembutsu, A | 1 |
| Bates, NP; Boven, E; Braybrooke, JP; Cheverton, PD; Dobbs, N; Pinedo, HM; Ruijter, R; Talbot, DC | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Coyle, J; De Jager, RL; Ducharme, M; Figueroa, JA; Garrison, MA; Geyer, CE; Hammond, LA; Rowinsky, EK; Schwartz, G; Smetzer, L; Takimoto, CH; Tolcher, AW | 1 |
| Büchler, MW; Cheverton, P; Friess, H; Kleeff, J; Langman, S; Wanders, J; Wente, MN | 1 |
| Hashida, M; Kuga, H; Ochi, Y; Shiose, Y; Yamashita, F | 1 |
| Aonuma, M; Ejima, A; Hirota, Y; Kumazawa, E; Mitsui, I; Ohsuki, S; Sato, K; Sugimori, M; Terasawa, H; Uoto, K | 1 |
| Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
| Coyle, J; De Jager, RL; Drengler, R; Eckhardt, SG; Geyer, CE; Hammond, LA; Johnson, TR; Rizzo, J; Rowinsky, EK; Schwartz, G; Smetzer, L; Tolcher, A; Von Hoff, DD | 1 |
| Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Raymond, E; Rixe, O | 1 |
| Coyle, J; De Jager, R; Ducharme, MP; Dumas, P; Hoff, PM; Lassere, Y; Lee, JJ; Pazdur, R; Royce, ME | 1 |
| Coyle, J; De Jager, RL; Ducharme, MP; Hollywood, E; Ilson, D; Kelsen, D; Kemeny, N; Kleban, S; O'Reilly, E; Saltz, LB; Schwartz, GK; Sharma, S | 1 |
| Nishiyama, M; Okamoto, R; Okamura, T; Park, JS; Sekikawa, T; Sparreboom, A; Takano, H; Tanimoto, K; Verweij, J; Yamamoto, W | 1 |
7 trial(s) available for dx 8951 and Benign Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2003 |
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Time Factors | 2003 |
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Delayed-Action Preparations; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors | 2005 |
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 2000 |
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Vomiting | 2000 |
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2001 |
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors | 2001 |
9 other study(ies) available for dx 8951 and Benign Neoplasms
| Article | Year |
|---|---|
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; DNA; DNA Topoisomerases, Type I; Humans; Mice; Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Topoisomerase I Inhibitors | 2022 |
Antigen-independent tumor targeting by CBX-12 (alphalex
Topics: Animals; Camptothecin; Cell Line, Tumor; Immunity; Immunotherapy; Neoplasms; Tumor Microenvironment | 2022 |
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Damage; Humans; Mice; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols | 2023 |
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Camptothecin; Cell Proliferation; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Macaca fascicularis; Male; Mice; Mice, Inbred NOD; Mice, Nude; Neoplasms; Rats; Receptor, ErbB-3; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cathepsins; Cell Line, Tumor; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Humans; Hydrolysis; Liver; Mice; Neoplasm Transplantation; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2007 |
A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Solubility; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured; Water | 1995 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glutathione; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |